Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Free Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Free cash flow grows 73.3% year over year

Q4 FY2025 free cash flow of $1.49M (cash outflow) rose 73.3% year over year. Sequentially, it rose 68.0% from the prior quarter.

Context

  • Free cash flow grew in size in 2 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$1.49M+68.0% QoQ
Last fiscal yearDec 2025
-$3.94M+53.3% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.3%——
1 year+53.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(3.94M) USD
Year-over-year change
-53.3%

Free Cash Flow vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 free cash flow of $3.94M is the smallest of the 8 companies compared; the peer median is $87.42M.
  • Its year-over-year change of +53.3% is the 2nd highest of 6, against a peer median of -23.5%.
PLYX Competitors Peer median
Free Cash Flow for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CBIOCrescent Biopharma, Inc.LTM Mar 2026$148.43M -8786.2%+15.9%1249.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$134.42M -23.5%-8.0%433609.7%
JBIOJade Biosciences, Inc.LTM Mar 2026$116.59M —+34.1%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.42M -8.8%—309.7%
KLRSKalaris Therapeutics IncLTM Mar 2026$49.09M —+64.1%—
PTHSPelthos Therapeutics Inc.LTM Mar 2026$35.38M +698.1%+143.7%127.7%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$31.28M -26.0%-3.8%—
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$3.94M +53.3%——
Peer median (excluding PLYX) $87.42M-23.5%+25.0%779.4%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.